Overview

AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy

Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine whether Fludarabine in combination with cytarabine is more effective than high-dose cytarabine in post-remission therapy for patients with AML1-ETO acute myeloid leukemia.
Phase:
Phase 4
Details
Lead Sponsor:
Changhai Hospital
Treatments:
Cytarabine
Fludarabine
Fludarabine phosphate
Vidarabine